

---

## Index Authors

### Volume 7 (2021)

- Agung Dewi Sekar, 75  
Agus Eka Darwinata, 93  
Agus Indra Yudhistira Diva Putra, 93  
Aida Fahira Rachma, 106  
Alfian Nur Rosyid, 122  
Alfian Nurfaizi, 59  
Ali Assagaf, 1  
Anang Endaryanto, 106  
Andreas Makmur, 114  
Anita Nur Charisma, 19  
Ariani Permatasari, 152  
Arie Gradiyanto Nugroho, 134  
Arie Utariani, 46  
Arief Bakhtiar, 59  
Aulia Rahman, 114  
Budi Utomo, 8  
Budi Yanti, 70  
Budiono Budiono, 53  
Catur Agustiyanto, 152  
Deasy Fetarayani, 106  
Diska Hanifah Nurhayati, 46  
Edijono Edijono, 134  
Erna Kusumawardhani, 1  
Evelyn Nathania, 127  
Faradila Nur Aini, 86  
Gadis Meinar Sari, 59  
Haryati Haryati, 1  
Herley Windo Setiawan, 122  
Herman Saputra, 14  
Hubah Asyiroh, 8  
I Gusti Ayu Sri Mahendra Dwi, 14  
I Komang Rusgi Yandi, 65  
Ida Ayu Jasminarti Dwi  
Kusumawardani, 14  
Indra Yovi, 114  
Ira Dharmawati, 46  
Ira Nurrasyidah, 1  
Ira Nurrasyidah, 100  
Irmis Syafa'ah, 86  
Irmis Syafa'ah, 139  
Isa Ansori, 100  
Isnin Anang Marhana, 59  
Isnin Anang Marhana, 65  
Isti Mardiana Soetartio, 145  
Jahja Teguh Widjaja, 127  
Kuntaman Kuntaman, 75  
Made Indira Dianti Sanjiwani, 93  
Mauliza Mauliza, 70  
Megawati Rif'atyyah Nozomi Guntur, 27  
Mohamad Isa, 1  
Muhammad Bagus Fidiandra, 53  
Ni Wayan Candrawati, 14  
Novita Andayani, 70  
Nur Prasetyo Nugroho, 79  
Nyoman Budhi Wirananda Setiawan, 93  
Prastuti Asta Wulaningrum, 122  
Putu Yuliawati, 14  
Resti Yudhawati, 27  
Retno Asih Setyoningrum, 8  
Retno Asih Setyoningrum, 46  
Retno Asih Setyoningrum, 106  
Rosantia Sarassari, 75  
Soedarsono Soedarsono, 36  
Soedarsono Soedarsono, 53  
Soedarsono Soedarsono, 75  
Soraya Riefani, 100  
Sri Melati Munir, 114  
Triya Damayanti, 145  
Tutik Kusmiati, 79  
Venny Singgih, 14  
Widati Fatmaningrum, 8  
Winariani Koesoemoprodjo, 19  
Wiwin Is Effendi, 122  
Yuliza Yuliza, 122

---

# Index Subjects

## Volume 7 (2021)

- Allergic asthma, 106  
Allergy, 79  
Amoebiasis, 134  
Anti interleukin-4/interleukin-13, 27  
Anti interleukin-5, 27  
Anti interleukin-17, 27  
Anti-tuberculosis, 65  
Appendicular tuberculosis, 122  
Asthma, 27  
Asthma, 145  
Asthma severity, 106  
Blood eosinophils, 59  
Candidiasis, 127  
Cerebellum, 65  
Chest X-ray, 114  
Children, 8  
Children, 46  
Clinical characteristics, 1  
CNS TB, 65  
Comorbidities, 1  
Completed treatment outcome, 19  
COPD, 145  
COPD exacerbations, 59  
COVID-19, 1  
COVID-19, 70  
COVID-19, 100  
COVID-19, 114  
COVID-19, 139  
Death, 1  
Desensitization, 79  
Diagnosis delay, 53  
Drug challenge, 79  
Empyema, 75  
Exclusive breastfeeding, 106  
Farmer's lung disease, 152  
FEV1% predicted, 59  
Fluidopneumothorax, 86  
Fungal pneumonia, 127  
Geriatrics, 70  
Gonitis tuberculosis, 19  
Granulocyte macrophage-colony stimulating factor, 93  
Gut-lung axis, 93  
Heimlich valve, 86  
Histopathological examination, 122  
Hospital-acquired pneumonia, 46  
Human & disease, 152  
Human & medicine, 145  
Hypersensitivity pneumonitis, 152  
Infectious disease, 100  
Infectious disease, 114  
Infectious disease, 122  
Infectious disease, 127  
Infectious disease, 134  
Infectious disease, 139  
Knee joint tuberculosis, 19  
Laboratory findings, 1  
Lung abscess, 134  
Lung adenocarcinoma, 14  
Mechanical ventilation, 139  
Mesenchymal stem cell, 145  
Mortality, 46  
Neovascular glaucoma, 14  
New drugs and treatment regimens, 36  
Non-invasive ventilation, 139  
Obesity, 70  
Occupational lung disease, 152  
Omalizumab, 27  
Orbital metastases, 14  
Osteoarthritis, 70  
Patient delay, 53  
Pneumothorax, 86  
Polymerase chain reaction (PCR), 100  
Post COVID-19, 127  
Probiotic, 93  
Public health, 106

Pulmonary amoebiasis, 134  
Quality of life, 106  
Rapid diagnostic test (RDT), 100  
Recurrent respiratory infection, 8  
Repurposed drugs, 36  
Risk factor, 46  
Risk factors, 8  
SARS-CoV-2, 100  
Secondary infection, 127  
Severity, 114  
Streptococcus anginosus group, 75  
Streptococcus constellatus, 75  
Surgery, 122  
System delay, 53  
TB and DR-TB regimen, 36  
Tuberculosis epidemiology, 53  
Tuberculosis, 65  
Tuberculosis, 79  
Tuberculosis, 93  
Tuberculosis, 122  
Upper respiratory tract infection, 8

## GUIDELINES FOR AUTHOR

JR publishes articles on all aspects of pulmonary- and respiratory-related disciplines. The article is submitted directly to <https://e-journal.unair.ac.id/JR/index>. Articles are considered for publication on condition that they have not been previously published or submitted for publication by other journals. Articles can be classified as original articles, case reports, or literature reviews that inform readers about current issues, innovative cases, rare case, and article reviews in the field of pulmonary and respiratory.

Articles must be between **10 to 15 pages in length**. Manuscripts must be typed on a word processor and submitted in the form of a soft copy file. The obligatory Times New Roman font should be in size 14 pt for the title and 12 pt for all other sections of text. Headlines should be written in bold with any Latin names presented in italics. Manuscripts must be of A4 format typed with one and a half space between lines and a 2.5 cm (1 inch)-wide margin. Authors are strongly advised to follow the manuscript preparation guidelines provided below.

### 1. FORMAT FOR ORIGINAL ARTICLE (RESEARCH REPORT)

- **Title:** brief, specific, informative, and written in English. It must contain **a maximum of ten words** (not exceeding a total of 40 letters and spaces) with the first word starting with a capital letter.
- **Name(s) of Author(s):** should include author(s)' full name(s), mailing address(es) for proofs, name(s), and address(es) of the department(s) to which the work should be attributed listed sequentially using a number (<sup>1</sup>) symbol.

#### Example:

Alfian Nur Rosyid<sup>1</sup>, Han Chen Tsu<sup>2</sup>, Sergey Tjulandin<sup>3</sup>, and Koichi Matsuda<sup>4</sup>

<sup>1</sup> Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya - Indonesia

<sup>2</sup> Department of Respiratory Medicine, Shanghai Chest Hospital, Jiao Tong University, Shanghai - China

<sup>3</sup> Department of Clinical Pharmacology and Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow - Russia

<sup>4</sup> Division of Pulmonary Medicine, Department of Medicine, Kobe University, Kobe - Japan

- **Introduction:** State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results. Explain how you

addressed the problem and clearly state the aims of your study. Please describe in narrative format and not using sub-chapter. **This article should not exceed 4000 words.** (Times New Roman font 12)

- **Methods:** Explain in detail about the research design, settings, time frame, variables, population, samples, sampling, instruments, data analysis, and information of ethical clearance fit test. This chapter may be divided into sections if several methods are used. (Times New Roman font 12)
- **Results:** This section may be further divided into subsections with subheading. Describe the significance of your findings and the most important part of your manuscript. Follow a logical stream of thought; in general, the interpretation as well as the experimental conclusions that can be drawn. (Times New Roman font 12)
- **Discussion:** Authors should explain how the results relate to the hypothesis presented as the basis of the study and provide a succinct explanation of the implications of the findings, particularly in relation to previous related studies and potential future directions for research. The content of the discussion section includes: the explanation of results, references to previous research, deduction, and hypothesis.
- **Conclusion:** This should clearly explain the main conclusions of the article, highlighting its importance and relevance as well as suggestion or recommendation for further research.
- **References:** Reference lists are arranged according to Vancouver writing style. Reference list is not included in the abstract and resume. Preferably use references from scientific articles (with issues **not exceeding the last 5 years**) and textbooks **maximum published in the last 10 years**. The author can use special applications for bibliography such as: [Mendeley®](#), [Zotero®](#), [EndNote®](#), and Reference Manager®.

#### Reference for journal articles:

1. Muttarak M, Peh WCG. Case 91: Tuberculous Epididymo-orchitis. *Radiology*. 2018;238(2):748-751. doi:10.1148/radiol.2382031851
2. Christiani D, Wang X, Pan L, Zhang H, Sun B, Dai H. Longitudinal changes in pulmonary function and respiratory symptoms in cotton textile workers. A 15-yr follow-up study. *Am J Respir Crit Care Med*. 2011;163(4):847–53

#### Reference for a Book:

1. Selman M, Carillo G, Navarro C, Gaxiola M. Hypersensitivity Pneumonitis. In: *Pulmonary Arterial Hypertension and Interstitial Lung Diseases*. LLC: Humana Press; 2017. p.1391

#### Reference for a Website:

1. Force, W. Global Strategy for Asthma Management and Prevention [serial online] 2019 Jan-Mar [cited 2020 May 5]. Available from: URL: <http://www.ginasthma.org>.

#### Reference for Proceeding:

1. Yoshiro J, Mamoto H, editors. Recent advances in clinical neurophysiology. Proceedings of the 24th Congress of the APSR: 2019 Nov 14-17; Kyoto, Japan. Amsterdam: Elsevier; 2020.

## 2. FORMAT FOR CASE REPORTS:

- **Title:** brief, specific, informative, and written in English. It must contain a **maximum of ten words** (not exceeding a total of 40 letters and spaces) with the first word starting with a capital letter.
- **Name(s) of Author(s):** should include author(s)' full name(s), mailing address(es) for proofs, name(s), and address(es) of the department(s) to which the work should be attributed listed sequentially using a number (<sup>1</sup>) symbol.

### Example:

Alfian Nur Rosyid<sup>1</sup>, Han Chen Tsu<sup>2</sup>, Sergey Tjulandin<sup>3</sup>, and Koichi Matsuda<sup>4</sup>

<sup>1</sup> Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya - Indonesia

<sup>2</sup> Department of Respiratory Medicine, Shanghai Chest Hospital, Jiao Tong University, Shanghai - China

<sup>3</sup> Department of Clinical Pharmacology and Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow - Russia

<sup>4</sup> Division of Pulmonary Medicine, Department of Medicine, Kobe University, Kobe - Japan

- **Introduction:** State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results. Explain how you addressed the problem and clearly state the aims of your study. Please describe in narrative format and not using sub-chapter. **This article should not exceed 3500 words.** (Times New Roman font 12)
- **Case:** This section content the medical case about patient condition, time frame, disease progression laboratory finding, differential diagnose and treatment uprightness. Explain the assessment and the decision choose to treat patient. (Times New Roman font 12)
- **Discussion:** Explain the most important finding in the case that unusual or remarkable. Explicate the mechanism/pathophysiology of injury with adequate basis or following guideline (using diagram if author would like to). (Times New Roman font 12)
- **Conclusion:** This part should explain the main summary of the article, highlighting its importance and relevance as well as suggestion or recommendation for further case. (Times New Roman font 12)
- **References:** Reference lists are arranged according to Vancouver writing style. Reference list is not included in the abstract and resume. Preferably use references from

scientific articles (with issues **not exceeding the last 5 years**) and textbooks **maximum published in the last 10 years**. The author can use special applications for bibliography such as: [Mendeley®](#), [Zotero®](#), [EndNote®](#), and Reference Manager®.

#### Reference for journal articles:

1. Muttarak M, Peh WCG. Case 91: Tuberculous Epididymo-orchitis. *Radiology*. 2018;238(2):748-751. doi:10.1148/radiol.2382031851
2. Christiani D, Wang X, Pan L, Zhang H, Sun B, Dai H. Longitudinal changes in pulmonary function and respiratory symptoms in cotton textile workers. A 15-yr follow-up study. *Am J Respir Crit Care Med*. 2011;163(4):847–53

#### Reference for a Book:

1. Selman M, Carillo G, Navarro C, Gaxiola M. Hypersensitivity Pneumonitis. In: *Pulmonary Arterial Hypertension and Interstitial Lung Diseases*. LLC: Humana Press; 2017. p.1391

#### Reference for a Website:

1. Force, W. Global Strategy for Asthma Management and Prevention [serial online] 2019 Jan-Mar [cited 2020 May 5]. Available from: URL: <http://www.ginasthma.org>.

#### Reference for Proceeding:

1. Yoshiro J, Mamoto H, editors. Recent advances in clinical neurophysiology. Proceedings of the 24th Congress of the APSR: 2019 Nov 14-17; Kyoto, Japan. Amsterdam: Elsevier; 2020.

### **3. FORMAT FOR LITERATURE REVIEWS:**

- **Title:** brief, specific, informative, and written in English. It must contain **a maximum of ten words** (not exceeding a total of 40 letters and spaces) with the first word starting with a capital letter.
- **Name(s) of Author(s):** should include author(s)' full name(s), mailing address(es) for proofs, name(s), and address(es) of the department(s) to which the work should be attributed listed sequentially using a number (1) symbol.

#### **Example:**

Alfian Nur Rosyid<sup>1</sup>, Han Chen Tsu<sup>2</sup>, Sergey Tjulandin<sup>3</sup>, and Koichi Matsuda<sup>4</sup>

<sup>1</sup> Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya - Indonesia

<sup>2</sup>Department of Respiratory Medicine, Shanghai Chest Hospital, Jiao Tong University, Shanghai - China

<sup>3</sup>Department of Clinical Pharmacology and Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow - Russia

<sup>4</sup>Division of Pulmonary Medicine, Department of Medicine, Kobe University, Kobe - Japan

- **Introduction:** The introduction state the objectives of the article, consits the reasons for the study, formulation of the problem, and statement of purpose. Describe using narrative format and without sub-chapter. **This article should not exceed 4000 words.** (Times New Roman font 12). (Times New Roman font 12)
- **Review:** This section can be further divided into sub-sections. Explain the topic with sufficient and scientific evidence. Follow the logical thought; in general, so that interpretation can be drawn. (Times New Roman font 12)
- **Summary:** This part should explain the main summary of the article, highlighting its importance and relevance as well as suggestion or recommendation for further research. (Times New Roman font 12)
- **References:** Reference lists are arranged according to Vancouver writing style. Reference list is not included in the abstract and resume. Preferably use references from scientific articles (with issues **not exceeding the last 5 years**) and textbooks **maximum published in the last 10 years**. The author can use special applications for bibliography such as: [Mendeley®](#), [Zotero®](#), [EndNote®](#), and Reference Manager®.

#### Reference for journal articles:

1. Muttarak M, Peh WCG. Case 91: Tuberculous Epididymo-orchitis. *Radiology*. 2018;238(2):748-751. doi:10.1148/radiol.2382031851
2. Christiani D, Wang X, Pan L, Zhang H, Sun B, Dai H. Longitudinal changes in pulmonary function and respiratory symptoms in cotton textile workers. A 15-yr follow-up study. *Am J Respir Crit Care Med*. 2011;163(4):847–53

#### Reference for a Book:

1. Selman M, Carillo G, Navarro C, Gaxiola M. Hypersensitivity Pneumonitis. In: *Pulmonary Arterial Hypertension and Interstitial Lung Diseases*. LLC: Humana Press; 2017. p.1391

#### Reference for a Website:

1. Force, W. Global Strategy for Asthma Management and Prevention [serial online] 2019 Jan-Mar [cited 2020 May 5]. Available from: URL: <http://www.ginasthma.org>.

#### Reference for Proceeding:



1. Yoshiro J, Mamoto H, editors. Recent advances in clinical neurophysiology. Proceedings of the 24th Congress of the APSR: 2019 Nov 14-17; Kyoto, Japan. Amsterdam: Elsevier; 2020.

## **SUBMISSION PREPARATION CHECKLIST**

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format.
3. Where available, URLs for the references have been provided.
4. The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
5. The text adheres to the stylistic and bibliographic requirements outlined in the [Author Guidelines](#), which is found in About the Journal.
6. If submitting to a peer-reviewed section of the journal, the instructions in [Ensuring a Blind Review](#) have been followed.

## **COPYRIGHT NOTICE**

1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under “the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.

## PRIVACY STATEMENT

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

## AUTHOR FEES

This journal charges the following author fees.

Article Submission: 0.00 (IDR)

Authors are required to pay an Article Submission Fee as part of the submission process to contribute to review costs.

If you do not have funds to pay such fees, you will have an opportunity to waive each fee. We do not want fees to prevent the publication of worthy work.

## SECTION POLICIES

### ARTICLES

Open Submissions       Indexed       Peer Reviewed

### ORIGINAL ARTICLE

Open Submissions       Indexed       Peer Reviewed

### CASE REPORT

Open Submissions       Indexed       Peer Reviewed

### REVIEW ARTICLE

Open Submissions       Indexed       Peer Reviewed

## PEER REVIEW PROCESS

This journal uses **double-blind review**, which means that both reviewer and author identities are concealed from the reviewers, and vice versa, throughout the review process. The article review process usually takes average **10 weeks**. This review period depends on the editors and reviewers duration in reviewing the manuscript.

The practice of peer review is to ensure that only good science is published. It is an objective process at the heart of good scholarly publishing and is carried out by all reputable scientific journals. Our referees play a vital role in maintaining the high standards *Transport Policy* and all manuscripts are peer reviewed following the procedure outlined below.

**Initial manuscript evaluation** The Editor first evaluates all manuscripts. It is rare, but it is possible for an exceptional manuscript to be accepted at this stage. Manuscripts rejected at this stage are insufficiently original, have serious scientific flaws, have poor grammar or English language, or are outside the aims and scope of the journal. Those that meet the minimum criteria are normally passed on to at least 2 experts for review.

**Type of Peer Review** *Transport Policy* employs double blind reviewing, where both the referee and author remain anonymous throughout the process.

**How the referee is selected** Whenever possible, referees are matched to the paper according to their expertise and our database is constantly being updated.

**Referee reports** Referees are asked to evaluate whether the manuscript: - Is original - Is methodologically sound - Follows appropriate ethical guidelines - Has results which are clearly presented and support the conclusions - Correctly references previous relevant work.

Language correction is not part of the peer review process, but referees may, if so wish, suggest corrections to the manuscript.

**How long does the review process take?** The time required for the review process is dependent on the response of the referees. Should the referee's reports contradict one another or a report is unnecessarily delayed, a further expert opinion will be sought. In rare cases for which it is extremely difficult to find a second referee to review the manuscript, or when the one referee's report has thoroughly convinced the Editor, decisions at this stage to accept, reject or ask the author for a revision are made on the basis of only one referee's report. The Editor's decision will be sent to the author with recommendations made by the referees, which usually includes verbatim comments by the referees. Revised manuscripts might be returned to the initial referees who may then request another revision of a manuscript.

**Final report** A final decision to accept or reject the manuscript will be sent to the author along with any recommendations made by the referees, and may include verbatim comments by the referees.

**Editor's Decision is final** Referees advise the editor, who is responsible for the final decision to accept or reject the article.

**Becoming a referee for *Transport Policy*** If you are not currently a referee for *Transport Policy* but would like to be considered as a referee, please contact the editor. The benefits of refereeing for *Transport Policy* include the opportunity to read see and evaluate the latest work in your research area at an early stage, and to contribute to the overall integrity of scientific research and its published documentation. You may also be able to cite your work for *Transport Policy* as part of your professional development requirements for various Professional Societies and Organizations.

## **PUBLICATION FREQUENCY**

Jurnal Respirasi is published three time in a year (January, May, & September) and contains 9 articles in each number of volume.

## **OPEN ACCESS POLICY**

This is an open access journal that all content is available for other users. Users are allowed to read, download, copy, search, print, or link to the full texts of the articles, without asking prior permission from the publisher or the author.

This journal provides immediate open access to its content on the principle that makes researches available freely to the public and supports a greater global exchange of knowledge.

## **ARCHIVING**

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration. [More...](#)

## **ARTICLE PROCESSING CHARGE**

### **a. Article Submission Fee : IDR 0 / USD 0**

No charge for manuscript submission.

### **b. Article Processing Charge: IDR 500,000 / USD 100**

The author pays a publication fee amounted to IDR 500,000 (Indonesian author) and USD 100 (non-Indonesian author) for each manuscript published in the journal.

### **c. Waiver Policy**

We consider individual waiver requests for articles in our journal. To apply for a waiver, please request one during the submission process to our email address. A decision on the waiver will normally be made within three working days. However, this journal does not charge for manuscript submission.

### **PLAGIARISM STATEMENT**

The editors of Jurnal Respirasi will screen all submitted manuscripts for plagiarism using **Turnitin** plagiarism checker. This journal does not accept any plagiarism in any manuscripts or it will be rejected immediately. The manuscript is passed if the similarity is less than 20%.

### **COPYRIGHT STATEMENT**

#### **1. As an author you (or your employer or institution) may do the following:**

- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a 'work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author's personal use or for company use, provided that the source and the copyright notice are indicated, the copies are not used in any way that implies JR endorsement of a product or service of any employer, and the copies themselves are not offered for sale.

All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal.

## **2. Requests from third parties**

Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use. Requests for all uses not included above, including the authorization of third parties to reproduce or otherwise use all or part of the article (including figures and tables), should be referred to JR by going to our website [here](#).

## **3. Author Online Use**

- **Personal Servers.** Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from JR, provided that the posted version includes a prominently displayed JR copyright notice and, when published, a full citation to the original publication, including a link to the article abstract in the journal homepage. Authors shall not post the final, published versions of their papers;
- **Classroom or Internal Training Use.** An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author's personal web site or the servers of the author's institution or company in connection with the author's teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
- **Electronic Preprints.** Before submitting an article to JR, authors frequently post their manuscripts to their own web site, their employer's site, or to another server that invites constructive comment from colleagues. Upon submission of an article to JR, an author is required to transfer copyright in the article to JR, and the author must update any previously posted version of the article with a prominently displayed JR copyright notice. Upon publication of an article by JR, the author must replace any previously posted electronic versions of the article with either (1) the full citation to the work with a Digital Object Identifier (DOI) or link to the article abstract in JR homepage, or (2) the accepted version only (not the final, published version), including the JR copyright notice and full citation, with a link to the final, published article in journal homepage.

## **4. Articles in Press (AiP) service**

JR may choose to publish an abstract or portions of the paper before we publish it in the journal. Please contact our production department immediately if you do not want us to make any such prior publication for any reason, including disclosure of a patentable invention.

## 5. Author/Employer Rights

If you are employed and prepared the article on a subject within the scope of your employment, the copyright in the article belongs to your employer as a work-for-hire. In that case, JR assumes that when you sign this form, you are authorized to do so by your employer and that your employer has consented to the transfer of copyright, to the representation and warranty of publication rights, and to all other terms and conditions of this form. If such authorization and consent have not been given to you, an authorized representative of your employer should sign this form as the author.

## 6. Legal Formal Aspect



JR ([p-ISSN: 2407-0831](#), [e-ISSN: 2621-8372](#)) is licensed under [Creative Commons Attribution-ShareAlike 4.0 International License](#).

## SUBMISSIONS

### ONLINE SUBMISSIONS

Already have a Username/Password for Jurnal Respirasi?

[GO TO LOGIN](#)

Need a Username/Password?

[GO TO REGISTRATION](#)

Registration and login are required to submit items online and to check the status of current submissions.

## JOURNAL CONTACT

### MAILING ADDRESS

Department of Pulmonology & Respiratory Medicine

Faculty of Medicine Universitas Airlangga

Jl. Mayjen Prof Dr. Moestopo 6-8 Surabaya 60286 Indonesia

### PRINCIPAL CONTACT

**Winariani Koesoemoprodjo, dr., Sp.P(K), MARS, FCCP**

Department of Pulmonology & Respiratory Medicine

Faculty of Medicine Universitas Airlangga

Jl. Mayjen Prof Dr. Moestopo 6-8 Surabaya 60286 Indonesia

Phone: +62817375335

Email: [respirasi@journal.unair.ac.id](mailto:respirasi@journal.unair.ac.id)

### SUPPORT CONTACT

**Laila Maulida Hidayah, S.KM.**

Phone: +6281249340825

Email: [respirasi@journal.unair.ac.id](mailto:respirasi@journal.unair.ac.id)



ISSN 2407-0831



9 772407 083009